Tristel sees a year of good trading results and invests in new markets
The company is looking to emerging healthcare markets where point-of-care diagnostic devices connected to smart phones require high-level disinfection
Manufacturer of infection prevention and contamination control products, Tristel has seen double digit sales for the year ended 30 June 2017.
Tristel’s lead technology is a proprietary chlorine dioxide formulation and the company addresses three distinct markets:
- Human Healthcare (hospital infection prevention – via the Tristel brand)
- Contamination Control (control of contamination in critical environments – via the Crystel brand)
- Animal Healthcare market the Anistel brand)
The company said turnover was up 19% to £20.3m (2016: £17.1m) and overseas sales were up 43% to £9.6m (2016: £6.7m), representing 47% of total sales (2016: 39%). EBITDA before share-based payments up 26% to £5.4m (2016: £4.3m). Pre-tax profit before share-based payments was up 24% to £4.1m (2016: £3.3m).
Paul Swinney, Chief Executive of Tristel plc, said: “We are pleased with the progress made this year. Sales and profitability exceeded both market expectations and our internal plan. The drivers were growth in our overseas operations, favourable exchange rates and the acquisition of our Australian distributor’s business.”
”The North American regulatory programme is progressing well, with our first submission made to the EPA. We were disappointed to learn in early October that there will be delay to the approval timetable, but this does not change our expectation of first sales in North America in financial year 2018-19.
“Our investment in MobileODT involves us for the first time in an emerging healthcare market — point-of-care diagnostic devices connected to smart phones that require high-level disinfection. We believe this represents a significant future opportunity for Tristel.”
